Sarepta's Strategy for FDA Approval of Duchenne Exon Skipping Therapy Follows Confirmatory Trial Setback

Sarepta’s Strategy for FDA Approval of Duchenne Exon Skipping Therapy Follows Confirmatory Trial Setback